Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

See all formats and pricing


Select Volume and Issue


Evaluation of serum levels of p53 in hepatocellular carcinoma in Egypt

Mohamed A. El Far1 / Mohamed A. Atwa2 / Raida S. Yahya3 / Mohamed A. El Basuni4





Corresponding author: Professor Mohamed A. El Far, Division of Biochemistry, Faculty of Sciences, Mansoura University, Mansoura, Egypt Phone: +20-10-1562520, Fax: +20-50-2246781,

Citation Information: Clinical Chemical Laboratory Medicine. Volume 44, Issue 5, Pages 653–656, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2006.091, May 2006

Publication History

August 31, 2005
February 6, 2006
Published Online:


Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-induced death. Somatic mutation of the p53 gene is the most common genetic abnormality so far described in human cancer and there is evidence that supports a high level of p53 alterations in HCC. The aim of this study was to investigate serum levels of p53 in Egyptian patients with HCC, and its relation to other prognostic factors such as tumor grade, α-fetoprotein (AFP), and liver function tests in an attempt to clarify their significance in the pathogenesis of the disease. Liver function tests were carried out and AFP and p53 levels were measured for all individuals studied. Our results show that detection of p53 increased the frequency of HCC prediction from 79.5% to 86.3%. Moreover, significant positive correlation between p53 and tumor size (cm) for tumor grade II and III was identified. In conclusion, serum concentration of p53 protein may be a convenient and useful non-invasive screening test for prediction of HCC.

Keywords: α-fetoprotein; hepatitis B virus (HBV); hepatitis C virus (HCV); hepatocellular carcinoma; p53

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Sayeh Ezzikouri, Pascal Pineau, and Soumaya Benjelloun
Journal of Medical Virology, 2013, Volume 85, Number 9, Page 1542
Fabio Domenici, Anna Rita Bizzarri, and Salvatore Cannistraro
Analytical Biochemistry, 2012, Volume 421, Number 1, Page 9
Abdelfattah M. Attallah, Gamal E. Shiha, Hisham Ismail, Seham E. Mansy, Rania El-Sherbiny, and Ibrahim El-Dosoky
Clinical Biochemistry, 2009, Volume 42, Number 6, Page 455
Joana D. Amaral, Rui E. Castro, Clifford J. Steer, and Cecília M.P. Rodrigues
Trends in Molecular Medicine, 2009, Volume 15, Number 11, Page 531
Xuxian Xiao, Qiongqiong He, and Kelong Huang
Medical Oncology, 2010, Volume 27, Number 4, Page 1200
Min Wu, Chen Mao, Qing Chen, Xin-Wei Cu, and Wei-Seng Zhang
Molecular Biology Reports, 2010, Volume 37, Number 1, Page 339

Comments (0)

Please log in or register to comment.